{"id":1009016,"date":"2026-10-09T16:33:26","date_gmt":"2026-10-09T20:33:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/"},"modified":"2026-10-09T16:33:26","modified_gmt":"2026-10-09T20:33:26","slug":"aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/","title":{"rendered":"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ALISO VIEJO, Calif., Oct.  09, 2026  (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX<sup>\u00ae<\/sup> (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (\u201cRSUs\u201d) covering 150,000 shares of the Company\u2019s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company\u2019s Compensation Committee of the Board of Directors on October 5, 2026 under the Company\u2019s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March 9, 2026. The award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of the RSU agreement covering the grant. The RSUs were granted as a material inducement to the employee\u2019s entering into employment with the Company in accordance with Section 711 of NYSE American LLC Company Guide.<\/p>\n<p>\n        <strong>About AEON Biopharma<\/strong>\n      <\/p>\n<p>AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX<strong><em><sup>\u00ae<\/sup><\/em><\/strong>. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau<strong><em><sup>\u00ae<\/sup><\/em><\/strong>. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rrgb216CjA2ZyKWRcQ5qNUQD4639deENBq2m3j4Q2Eapvhzf0nsMTey_G_izlgvySG4z9iF-VIxl4p8Wdow8AkHrE_ewrJQSFA9h12lOXEs=\" rel=\"nofollow\" target=\"_blank\">www.aeonbiopharma.com<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>Investor Contact:<br \/>Hershel Berry<br \/>Blueprint Life Science Group<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gLETGhyF528Kh8v55Kdsaj1ZRLcmk6AySe5cVP8IShgyDnnej0Ydp8VOYheS7ujunnPjuyNe9pfonygxCj4vg0wPTJrbisEp_RaVVIsi4hr_JAkn7r3l-5qa50PeqwvT\" rel=\"nofollow\" target=\"_blank\">hberry@bplifescience.com<\/a>\u00a0<\/p>\n<p>Source: AEON Biopharma<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NDY5ZTRjYjMtNDBiNy00MzBiLTk1YzQtNDA1MWQxMmZiMTg0LTEyMzMzMzEtMjAyNi0xMC0wOS1lbg==\/tiny\/AEON-Biopharma-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX\u00ae (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (\u201cRSUs\u201d) covering 150,000 shares of the Company\u2019s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company\u2019s Compensation Committee of the Board of Directors on October 5, 2026 under the Company\u2019s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1009016","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX\u00ae (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (\u201cRSUs\u201d) covering 150,000 shares of the Company\u2019s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company\u2019s Compensation Committee of the Board of Directors on October 5, 2026 under the Company\u2019s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March &hellip; Continue reading &quot;AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-09T20:33:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711\",\"datePublished\":\"2026-10-09T20:33:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/\",\"name\":\"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=\",\"datePublished\":\"2026-10-09T20:33:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/","og_locale":"en_US","og_type":"article","og_title":"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - Market Newsdesk","og_description":"ALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX\u00ae (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (\u201cRSUs\u201d) covering 150,000 shares of the Company\u2019s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company\u2019s Compensation Committee of the Board of Directors on October 5, 2026 under the Company\u2019s 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of the Company. The RSUs vest in four equal installments, 25% on each annual anniversary of March &hellip; Continue reading \"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-09T20:33:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711","datePublished":"2026-10-09T20:33:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/"},"wordCount":330,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/","name":"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=","datePublished":"2026-10-09T20:33:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjQ0OCM3ODg2ODAyIzIyMjE3Nzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-reports-inducement-grant-under-nyse-american-llc-company-guide-section-711\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1009016"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009016\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1009016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1009016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1009016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}